Market Announcement

19 March 2026

Amplia Therapeutics Limited (ASX: ATX) – Trading Halt

Trading in the securities of Amplia Therapeutics Limited ('ATX') will be halted at the request of ATX, pending the release of an announcement by ATX.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Monday, 23 March 2026; or
- the release of the announcement to the market.

ATX's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

ABN 16 165 160 841

19 March 2026

AMPLIA THERAPEUTICS LIMITED (ASX: ATX) - REQUEST FOR TRADING HALT

Pursuant to Listing Rule 17.1, Amplia Therapeutics Limited ACN 165 160 841 (the **Company** or **Amplia**) requests that ASX grant an immediate trading halt for all of Amplia's securities.

In accordance with Listing Rule 17.1, the Company advises that:

- the trading halt is requested pending an announcement regarding clinical trial results following a central reading of data;
- the trading halt is required to enable the Company to assess the new data and prepare an appropriate announcement in an orderly manner;
- Amplia requests that the trading halt remain in place until the earlier of such time as it makes an announcement and the commencement of trading on Monday 23 March 2026; and
- Amplia is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt.

This trading halt request was authorised for release by the Board of Amplia Therapeutics Limited.

- End -

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit **www.ampliatx.com** and follow Amplia on **X** (@ampliatx) and **LinkedIn**.

ABN 16 165 160 841

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the **ACCENT** trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.7 months has also been reported. A second trial – **AMPLICITY** – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.